RENAL CELL CARCINOMA:
MODERN TREATMENT OPTIONS

RCC is no longer treated with a single default regimen. Histology (clear cell vs papillary, chromophobe, collecting duct, or translocation RCC), risk stratification using the IMDC model, presence of sarcomatoid features, and prior therapy all change the optimal first-line and second-line choice. Many patients are started on older single-agent TKIs when a modern combination would offer significantly better outcomes. A structured review by a genitourinary oncology team — or a second opinion at a high-volume centre — is one of the most valuable steps after diagnosis or progression.

Localised disease (Stage I and II) For small renal masses, partial nephrectomy is preferred whenever feasible to preserve kidney function, and is increasingly performed robotically or laparoscopically. Radical nephrectomy remains standard for larger or anatomically complex tumours. Active surveillance is appropriate for selected small tumours under 4 cm in older or comorbid patients. Thermal ablation — cryoablation or radiofrequency ablation — is an alternative for small tumours when surgery is not ideal. Adjuvant pembrolizumab is now an option for patients with high-risk features after surgery, based on disease-free survival benefit. Locally advanced disease (Stage III) Stage III RCC, with regional lymph node involvement or extension into major veins, is typically managed with radical nephrectomy, sometimes including thrombectomy for tumour thrombus extending into the renal vein or inferior vena cava. Adjuvant pembrolizumab is recommended in eligible high-risk patients. Multidisciplinary planning is essential — these surgeries are best performed at high-volume centres. Metastatic clear cell RCC (Stage IV) First-line therapy for metastatic clear cell RCC is now built around immune checkpoint inhibitor combinations. Common regimens include pembrolizumab plus axitinib, pembrolizumab plus lenvatinib, nivolumab plus cabozantinib, and nivolumab plus ipilimumab (the dual checkpoint regimen, particularly favoured in intermediate and poor risk groups). Choice depends on IMDC risk group, sarcomatoid features, comorbidities, and tolerance for specific side effect profiles. Cytoreductive nephrectomy is no longer routine but remains valuable in selected patients with limited metastatic burden and good performance status. After progression on first-line therapy Second-line and later options include cabozantinib, axitinib, lenvatinib plus everolimus, tivozanib, and belzutifan — a HIF-2α inhibitor with activity in both VHL-associated and sporadic RCC. Sequencing depends on what was used first-line, tolerance, and emerging biomarker findings. Re-challenge with immunotherapy in selected patients, and clinical trials of next-generation HIF inhibitors, novel TKIs, and CAR-T or vaccine approaches, are all part of the modern conversation.

Papillary, chromophobe, collecting duct, medullary, and translocation RCCs behave differently from clear cell disease and respond differently to therapy. Cabozantinib has shown activity across several non-clear cell subtypes, and immunotherapy combinations are being studied actively. MET-driven papillary RCC may respond to MET inhibitors. SMARCB1-deficient medullary RCC often requires platinum-based chemotherapy combined with immunotherapy or trial agents. Sarcomatoid features — which can occur in any subtype — paradoxically respond particularly well to immune checkpoint inhibitor combinations. Accurate pathology review and biomarker testing are therefore essential before starting therapy.

While RCC has historically been treated without routine genomic testing, the picture is changing. NGS can identify VHL pathway alterations, MET mutations and amplifications, fumarate hydratase (FH) loss, SDHB deficiency, BAP1 and PBRM1 changes, and TFE3/TFEB fusions in translocation RCC. Germline testing is recommended when there is a family history, young age at diagnosis, bilateral or multifocal tumours, or specific histologies such as hereditary leiomyomatosis-associated RCC. CancerFax helps patients access reliable NGS panels and germline testing internationally when local availability is limited.

Case review — diagnosis, histology, IMDC risk, biomarkers, and prior treatment are reviewed to confirm whether the current pathway is optimal. Second opinion coordination — reports are shared with experienced genitourinary oncology specialists and multidisciplinary teams in India, China, Germany, the United States, and other regions. Biomarker and NGS access — if molecular testing has not been done, CancerFax helps arrange reliable panels, especially for non-clear cell and atypical cases. Treatment and trial matching — actionable findings are mapped to approved combinations, biosimilars, and clinical trials including HIF-2α inhibitors, novel TKIs, and immune-based regimens. Logistics and follow-up — admission, travel, interpreter support, and continuity of care after returning home are coordinated through a single point of contact.

Frequently Asked Questions

Answers to common questions from patients and families.